Ergoteles’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Ergoteles’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,139	Closed	-$83.8K	–	1870
2022 Q4	$83.8K	Buy	7,139 +4,908	+220%	+$86.6K	﹤0.01%	1241
2022 Q3	$47K	Sell	2,231 -16,577	-88%	-$447K	﹤0.01%	1445
2022 Q2	$456K	Buy	18,808 +11,572	+160%	+$394K	0.01%	879
2022 Q1	$360K	Buy	+7,236	New	+$358K	0.01%	783
2021 Q4	–	Sell	-5,704	Closed	-$532K	–	1672
2021 Q3	$532K	Buy	+5,704	New	+$542K	0.02%	554
2020 Q4	–	Sell	-1,353	Closed	-$116K	–	955
2020 Q3	$116K	Buy	+1,353	New	+$158K	0.02%	529

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ergoteles's VBIV Position: Q1 2023 in Review

Ergoteles sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 7,139 shares — an estimated $83.8K sold.

Ergoteles first reported a position in VBIV in Q3 2020 and held it in 6 quarters. The position peaked at $532K in Q3 2021. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

Ergoteles reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 7,139 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $83.8K.
Ergoteles first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2020 and held it in 6 quarters.
Ergoteles's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $532K in Q3 2021.
95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.